Bonesupport Holding Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Bonesupport Holding has been growing earnings at an average annual rate of 62.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 36.9% per year. Bonesupport Holding's return on equity is 13.7%, and it has net margins of 11.1%.
Wichtige Informationen
62.2%
Wachstumsrate der Gewinne
63.6%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 0.7% |
| Wachstumsrate der Einnahmen | 36.9% |
| Eigenkapitalrendite | 13.7% |
| Netto-Marge | 11.1% |
| Nächste Ertragsaktualisierung | 25 Feb 2025 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
Oct 31
We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth
Mar 16We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn
Nov 06Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability
Mar 31Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares
Mar 04Aufschlüsselung der Einnahmen und Ausgaben
Wie Bonesupport Holding Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 814 | 91 | 575 | 72 |
| 30 Jun 24 | 735 | 289 | 539 | 65 |
| 31 Mar 24 | 656 | 267 | 497 | 59 |
| 31 Dec 23 | 591 | 245 | 462 | 57 |
| 30 Sep 23 | 522 | 214 | 420 | 54 |
| 30 Jun 23 | 448 | -30 | 383 | 54 |
| 31 Mar 23 | 382 | -51 | 342 | 53 |
| 31 Dec 22 | 329 | -68 | 312 | 53 |
| 30 Sep 22 | 287 | -72 | 279 | 53 |
| 30 Jun 22 | 257 | -71 | 249 | 51 |
| 31 Mar 22 | 234 | -82 | 236 | 53 |
| 31 Dec 21 | 213 | -86 | 221 | 53 |
| 30 Sep 21 | 205 | -88 | 212 | 55 |
| 30 Jun 21 | 198 | -96 | 214 | 55 |
| 31 Mar 21 | 182 | -92 | 197 | 54 |
| 31 Dec 20 | 181 | -101 | 201 | 58 |
| 30 Sep 20 | 174 | -115 | 207 | 60 |
| 30 Jun 20 | 165 | -127 | 204 | 66 |
| 31 Mar 20 | 166 | -151 | 227 | 68 |
| 31 Dec 19 | 155 | -161 | 226 | 69 |
| 30 Sep 19 | 132 | -166 | 213 | 68 |
| 30 Jun 19 | 108 | -191 | 215 | 67 |
| 31 Mar 19 | 98 | -182 | 199 | 68 |
| 31 Dec 18 | 97 | -176 | 192 | 66 |
| 30 Sep 18 | 101 | -182 | 181 | 68 |
| 30 Jun 18 | 119 | -146 | 163 | 65 |
| 31 Mar 18 | 128 | -132 | 148 | 66 |
| 31 Dec 17 | 129 | -129 | 150 | 61 |
| 30 Sep 17 | 132 | -112 | 153 | 56 |
| 30 Jun 17 | 126 | -124 | 154 | 54 |
| 31 Mar 17 | 114 | -124 | 160 | 42 |
| 31 Dec 16 | 105 | -110 | 140 | 38 |
| 31 Dec 15 | 62 | -60 | 88 | 19 |
| 31 Dec 14 | 41 | -75 | 61 | 17 |
Qualität der Erträge: BONEX has a high level of non-cash earnings.
Wachsende Gewinnspanne: BONEX's current net profit margins (11.1%) are lower than last year (41%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: BONEX has become profitable over the past 5 years, growing earnings by 62.2% per year.
Beschleunigtes Wachstum: BONEX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: BONEX had negative earnings growth (-57.6%) over the past year, making it difficult to compare to the Biotechs industry average (-20.8%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: BONEX's Return on Equity (13.7%) is considered low.